Skip to main content

Table 3 Methylation markers by patient characteristics

From: NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas

 

CCNA1

NDN

CD1A

DCC

p16

GADD45

 

median (range)

p

median (range)

p

median (range)

p

median (range)

p

median (range)

p

median (range)

p

Age

            

 <40 years

19.5 (14.5, 64.7)

0.4

40.8 (34.5, 72.8)

0.4

78.6 (56.8, 91.2))

0.02

21.3 (9.9, 62.3)

0.4

3.1 (0.6, 25.0)

0.5

1.5 (1.0, 2.8)

0.5

 40-60

25.8 (3.0, 90.5)

 

44.6 (10.8, 84.2)

 

71.0 (22.2, 93.9)

 

33.2 (3.1, 85.8)

 

2.3 (0, 70.1)

 

1.4 (0, 3.9)

 

 ≥60

27.3 (5.5, 77.0)

 

43.9 (11.2, 84.9)

 

68.6 (21.4, 90.9)

 

33.7 (3.0, 79.8)

 

2.2 (0, 59.8)

 

1.4 (0, 16.0)

 

HPV

            

 Positive

33.3 (3.0, 76.0)

<0.001

52.7 (14.0, 84.9)

<0.001

77.6 (25.1, 93.9)

<0.001

44.7 (3.1, 85.8)

<0.001

1.9 (0, 59.8)

<0.001

1.4 (0.4, 3.9)

0.8

 Negative

20.9 (5.5, 90.5)

 

40.0 (10.8, 80.3)

 

65.4 (21.4 (92.2)

 

26.0 (3.0, 83.3)

 

2.5 (0, 70.1)

 

1.4 (0, 16)

 

Pack Years

            

 0

26.6 (3.0, 90.5)

0.2

46.4 (14.0, 84.2)

0.01

79.7 (47.2, 93.9)

<0.001

36.7 (3.1, 79.8)

0.1

2.2 (0, 26.9)

0.7

1.5 (0.3, 3.7)

0.2

 0-10

31.5 (13.3, 63.3)

 

45.9 (24.6, 75.7)

 

70.5 (32.4, 91.1)

 

40.5 (10.8, 71.7)

 

2.1 (0, 46.6)

 

1.4 (0.4, 16.0)

 

 10-20

23.6 (6.8, 64.8)

 

46.4 (10.8, 76.8)

 

73.0 (26.7, 91.7)

 

32.7 (6.1, 75.1)

 

2.2 (0, 70.1)

 

1.6 (0.7, 3.9)

 

 20+

25.5 (6.3, 77.0)

 

41.3 (11.2, 84.9)

 

64.2 (21.4, 92.0)

 

31.4 (3.0, 85.8)

 

2.4 (0, 59.8)

 

1.4 (0, 3.9)

 

Tobacco

            

 Current

25.5 (6.3, 76.0)

0.8

45.0 (10.8, 84.9)

0.02

69.5 (25.1, 91.7)

<0.001

39.5 (4.2, 83.3)

0.03

2.2 (0, 70.1)

0.7

1.4 (0, 16)

0.5

 Former

25.6 (6.8, 77.0)

 

42.2 (11.2, 80.3)

 

64.4 (21.4, 90.0)

 

29.3 (3.0, 85.8)

 

2.4 (0, 46.6)

 

1.4 (0, 3.9)

 

 Never

26.6 (3, 90.5)

 

46.4 (14.0, 84.2)

 

79.7 (47.2, 93.9)

 

35.7 (3.1, 79.8)

 

2.2 (0, 26.9)

 

1.5 (0.3, 3.7)

 

Site

            

 Larynx/Glottic

24.5 (8.0, 90.5)

<0.001

41.2 (11.2, 84.9)

<0.001

56.2 (21.6, 92.2)

<0.001

26.3 (3.1, 83.3)

<0.001

2.4 (0, 51.8)

<0.001

1.4 (0, 3.9)

0.02

 Oral Cavity

22.0 (5.5, 77.0)

 

40.0 (10.8, 62.8)

 

70.6 (21.4, 90.2)

 

28.4 (3.0, 67.2)

 

2.6 (0, 70.1)

 

1.4 (0, 16.0)

 

 Oropharynx

32.3 (3.0, 76.0)

 

52.7 (21.8, 84.2)

 

77.5 (21.6, 93.9)

 

42.5 (6.1, 81.6)

 

2.0 (0, 39.9)

 

1.4 (0.4, 3.9)

 

 Hypopharynx

15.6 (9.0, 64.0)

 

44.2 (17.2, 91.0)

 

60.5 (25.1, 90.6)

 

54.5 (12.3, 85.8)

 

2.6 90, 59.8)

 

1.1 (0, 1.6)

 

Stage

            

 I/Cis

27.5 (11.8, 77.0)

0.01

38.6 (11.2, 80.3)

<0.001

68.1 (30.3, 89.4)

0.8

26.7 (3.0, 67.2)

0.1

2.5 (0, 39.0)

0.1

1.3 (0, 3.5)

0.3

 II

22.4 (12, 74.3)

 

41.2 (17.2, 84.2)

 

68.8 (21.6, 88.3)

 

40.8 (7.9, 83.3)

 

2.3 (0, 59.8)

 

1.4 (0.6, 4.6)

 

 III

21.3 (6.8, 61.3)

 

40.4 (15.3, 69.7)

 

71.2 (21.4, 90.2)

 

28.8 (3.9, 75.1)

 

2.6 (0, 70.1)

 

1.5 (0, 16.0)

 

 IV

27.6 (3.0, 90.5)

 

46.8 (10.8, 84.9)

 

70.5 (21.6, 93.9)

 

35.9 (3.1, 85.8)

 

2.2 (0, 51.8)

 

1.4 (0, 3.9)

 

Comorbidities

            

 None

29.5 (6.3, 74.3)

0.4

46.0 (20.2, 84.2)

0.3

74.8 (32.4, 93.9)

0.006

33.1 (5.6, 75.2)

0.6

2.5 (0, 39.9)

0.4

1.5 (0.4, 4.6)

0.1

 Mild

25.5 (3.0, 77.0)

 

43.3 (10.8, 84.9)

 

69.5 (21.6, 92.0)

 

35.4 (3.0, 85.8)

 

2.2 (0, 70.1)

 

1.4 (0, 16.0)

 

 Moderate

23.0 (6.8, 90.5)

 

44.0 (15.0, 79.3)

 

69.2 (21.4, 92.2)

 

29.8 (3.5, 79.8)

 

2.2 (0, 59.8)

 

1.3 (0, 3.9)

 

 Severe

30.5 (13.5,63.3)

 

44.6 (11.2, 80.3)

 

65.4 (21.6, 85.1)

 

43.0 (6.2, 83.3)

 

1.8 (0, 51.8)

 

1.2 (0, 3.9)

 

Gender

            

 Male

26.5 (3.0, 90.5)

0.2

45.6 (13.0, 84.9)

0.003

69.9 (21.4, 93.9)

0.4

36.1 (3.1, 85.8)

0.002

2.3 (0, 70.1)

0.9

1.4 (0, 3.9)

0.5

 Female

23.8 (6.3, 77.0)

 

40.5 (10.8, 68.9)

 

69.5 (21.6, 91.7)

 

25.4 (3.0, 75.1)

 

2.1 (0, 46.6)

 

1.4 (0, 16.0)

 
  1. Distribution of methylation markers across patient characteristics. p-values calculated by Kruskal-Wallis tests. Methylation values are expressed as percentages